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Background: The National AIDS Control Organization of India has been providing free second line antiretroviral
therapy (ART) since 2008. This observational study reports the survival and virologic suppression of patients on
second-line ART under programmatic condition and type of mutations acquired by those failing therapy.
Methods: 170 patients initiated on second-line therapy between 2008 and 2012 were followed up till 2013.
Viral Load (VL) was repeated at 6 months for all patients and at 12 months for those with VL >400 copies/ml at
6 months. Adequate virological response was defined as plasma HIV-1 VL <400 copies/ml and virological failure was
defined as VL >1000 copies/ml. Genotyping was done in 16 patients with virological failure.
Results: Out of 170 patients, 110 (64.7 %) were alive and on therapy and 35 (20.5 %) expired. In the first year the
occurrence of death was 13.7 /100 person years while between1 and 5 year it was 3.88 /100 person years. In the first
year, duration of immunological failure >12 months, weight <45 kg, WHO clinical stage 3 and 4 and WHO criteria CD4
count less than pretherapy baseline [hazard ratio HR 4.2. 15.8, 11.9 & 4.1 respectively] and beyond first year poor first
and second line adherence and first line CD4 count < 200/μL [HR 5.2,15.8, 3.3 respectively] had high risk of death.
119/152 (78.2 %) had adequate virological response and 27/152 (17.7 %) had virological failure. High viral load at
baseline and poor second line adherence (Odds Ratio 3.4 & 2.8 respectively) had increased risk of virological failure.
Among those genotyped, 50 % had major Protease Inhibitor mutation (M46I commonest) however 87.5 % were still
susceptible to darunavir.
Conclusions: Second line therapy has shown high early mortality but good virological suppression under
programmatic conditions.
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Of the 4.8 million people living with HIV (PLHIV) in
Asia, nearly half (49 %) are in India. There has been a
massive scale-up of antiretroviral therapy (ART) ser-
vices in India since the National AIDS Control
Organization (NACO) launched the ART centres
providing free antiretroviral drugs in 2004. As of
September 2014, there were 453 fully functional ART* Correspondence: tapadar@gmail.com
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(http://creativecommons.org/publicdomain/zecentres across the country providing free first line
ART to 810,339 PLHIVs [1]. With the increase in
number of patients on first line therapy it is envi-
sioned that a proportion of patients will experience
treatment failure and need second line ART regimens
over time. In 2008, NACO piloted a national strategy
for the provision of free second-line ART in India
and these drugs are being provided at 10 Centres of
Excellence and 16 ART Plus Centre. As on September
2014, 10,223 patients were receiving second line drugs
in the National program [1].
Similar to other resource-limited settings (RLS), access
to routine viral load testing to monitor therapy orrticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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the program. Patients suspected of treatment failure on
first line regimens based on WHO defined immunologic
or clinical criteria are subjected to viral load testing, and
only those with definitive virologic failure qualify for
switch to second-line ART. Like other RLS the only
second line ART available consists of a boosted protease
inhibitor (bPI) with two nucleoside reverse transcriptase
inhibitors (NRTIs).
Amongst the RLS, reports of efficacy and survival of
patients on second line regimens are available mostly
from Africa [2–4]. Although the second line ART pro-
gram has been launched by NACO for six years studies
to evaluate the survival and efficacy of the prevailing
second line regimen are lacking in the country. A recent
study from India has shown an excellent early outcome
of second line treatment [5]. In the near future, NACO
plans to consolidate the first and second line treatment
and launch third line ART [6]. Therefore, there is an ur-
gent need to evaluate the efficacy of the second line
therapy and to know the mutations acquired by those
failing therapy for the selection of an appropriate third
line regimen. This study was done to report the survival
and virologic suppression and their predictors in pa-
tients receiving Protease Inhibitor (PI) based second-line
ART under programmatic condition and to assess the
mutations acquired by those failing second line therapy.
Methods
Study site
This observational study was conducted at the ART
Centre of the Centre of Excellence (COE), of Banaras
Hindu University (BHU). The ART centre is one of the
largest in this region with 18,746 PLHIV registered in
HIV care and 4530 currently on first line ART. It is also
a referral centre for evaluation of patients suspected of
first line failure from 14 ART centres.
Study population
The study was approved by the Ethics Committee of the
Institute of Medical Sciences, Banaras Hindu University.
Data of all patients >15 years of age who were started on
second line therapy due to failure of first line ART at
COE BHU since the beginning of the program in De-
cember 2008 to December 2012 were included in this
study. Written informed consent from patients or their
guardians for children were taken for HIV drug resist-
ance genotyping.
The first line regimen recommended by NACO and
received by patients was Zidovudine + Lamivudine + Ne-
virapine if hemoglobin was >9gm/dl or Stavudine +
Lamivudine + Nevirapine if hemoglobin <9gm/dl. Efavir-
enz was substituted for Nevirapine in those taking anti-
tubercular drugs and those with Nevirapine toxicity.Patients on first line therapy were eligible for evaluation
for second-line ART if they had been receiving ART for
at least 6 months, and had demonstrated treatment
adherence of >95 %, and had WHO clinical or immuno-
logical failure as per NACO guidelines. Viral load esti-
mation was done in these patients and those with HIV
RNA >10,000 copies/mL were considered as first line
failure and started on second line therapy [7]. In May
2011, the cut off level of viral load for starting ART was
reduced to >5000 copies/ml by NACO [8].
All patients with first line failure between 2008 and
April 2011 were given a uniform second-line ART
regimen provided by NACO comprising of tenofovir
(TDF) + lamivudine (3TC) + zidovudine (AZT) + lopina-
vir/ritonavir (LPV/r). Zidovudine was excluded from the
regimen in patients with significant anemia (hemoglobin
less than 9 g/dL) or previous history of zidovudine in-
duced anemia. After May 2011, the second line ART pro-
vided by NACO was tenofovir with lamivudine and
Atazanavir/ritonavir (ATV/r).All new patients and those
who were previously on lopinavir based regimen were
shifted to this regimen [8]. In patients with concomitant
tuberculosis rifampicin was replaced by rifabutin without
any change in the ART regimen.
Patients were followed up monthly and CD4 count
(FACS Calibur Becton Dickinson Biosciences) was done
6 monthly for all patient. During each visit, patients
were counselled for adherence and evaluated for drug
toxicity, clinical improvement and opportunistic infec-
tions. Patient’s weight, clinical stage, functional status,
drug toxicity, adherence to ART medication, presence of
opportunistic infection, any change in therapy were
documented. Viral load (VL) was repeated by COBAS
TaqMan HIV-1 assay in all patients at 6 months, if it
was <400copies/ml at 6 months it was not repeated fur-
ther as per National guidelines. Patients with VL >400
copies/ml at 6 months, adherence was reinforced and VL
was repeated at 12 months. Adherence was calculated on
the basis of pill count at every visit by the formula:
Number of pills actually taken by a patient for a particular
time period/Number of pills prescribed for this time
period × 100. For analysis we compared those with >95 %
adherence at every visit with those with <95 % at any visit.
At the end of the month patients were labelled as ‘on
treatment’ if they picked up their drugs, ‘missed’ if they did
not pick up drugs for the month, dead if they expired and
‘transferred out’ if they were transferred out to another
ART centre. Those patients who did not come for 3 con-
secutive months were labelled as lost to follow up (LFU)
at the end of fourth month as per NACO guidelines.
HIV drug resistance (HIVDR) genotyping
The HIVDR genotyping was performed in patients with
viral load >1000 copies/ml on two occasions after
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at −70 °C were used for detection of HIVDR mutations
by in-house assay described in a previous study [9]. RNA
extraction from plasma samples were performed using
the NucliSENSEasyMAGTM (Biomerieux, Durham, NC)
automated nucleic acid extraction system according to the
manufacturer’s recommendations (NucliSENSEasyMAG
user manual, v1.1; BioMe’rieux, Boxtel, Netherlands). The
RobusT one step RT-PCR kit (FinnzymesOy, Finland) was
used to amplify the complete protease and RT region of
the pol gene. RT-PCR was performed as described previ-
ously using 2021 F and 4521R primers [10]. The nested
PCR was performed using the inner primer pair2135F and
3338R to get an amplified fragment of 2336 bp. A Gene
Amp PCR system 9700 thermal cycler (Applied Biosys-
tem, CA, USA) was used for all PCRs. DNA sequencing
was performed on 3100 DNA genetic analyzer (Applied
Biosystem, CA, USA) using a set of six specific primers
(2135 F, 2493 F, 3012 F, 2557R, 3117R, 3338R). The raw
sequence data from ABI 3100 genetic analyzer was assem-
bled, aligned and edited with the SeqScape v2.0 software
(Applied Biosystem, CA, USA). The quality of the se-
quences was assessed using the SQUAT software. The
HIVDR mutational analysis was performed using the on-
line “HIVdb Program: Sequence Analysis” program from
Stanford University [11].
Genotype sensitivity scores (GSS) for the prescribed
regimen at the time of second line failure were calcu-
lated based on the five Stanford HIVdb resistance
categories: susceptible or complete activity, potential
low-level resistance or good activity, low-level resistance
or partial activity, intermediate-level resistance or scarce
activity, high-level resistance or no activity correspond-
ing with scores of 1.00, 0.75, 0.50, 0.25, and 0.00, re-
spectively [12, 13]. Etravirine susceptibility scores (ESS)
were calculated using the scoring system described
by Vingerhoets et al. [14] and recommended by the
IAS-USA.
Statistical analysis
Data was extracted and was analysed using SPSS version
16.0. The data was presented as mean ± standard devi-
ation (SD) for continuous variables and frequency with
their respective percentages for categorical variables.
Patient characteristics was described in terms of median
with their inter quartile range (IQR) for skewed continu-
ous data. For categorical data Chi-square test and Fi-
scher Exact test was used and for continuous data
Student’s t test and Mann Whitney U test was used.
For efficacy analysis, virological response at one year
of therapy was observed. Adequate virological response
was defined as plasma HIV-1 VL <400 copies/ml, VL be-
tween 400 and 1000 copies /ml was defined as on-going
viremia and VL >1000 copies/ml was used to definevirological failure or treatment failure at one year.
Efficacy data was analyzed by an intention-to-treat (ITT)
i.e. among all patients included in the study and on-
treatment (OT) approach i.e. among those patients who
at least had a VL at six month. VL at six month was in-
cluded for analysis for those patients eligible for twelve
month viral load but it could not be done due to death
or LFU and for those who had adequate virological sup-
pression at 6 months.
To assess the predictors of treatment failure patients
with VL >1000 copies/ml were compared with those
with VL < 400copies/ml. To define predictors of treat-
ment failure, univariate analyses were performed with
the following determinants: age, gender, first-line ART
regimen (zidovudine versus stavudine), weight, CD4
count, clinical stage at the start of first and second-line
treatment, presence of tuberculosis, adherence, duration
of treatment of first and second-line therapy. A multi-
variate analysis was performed by using the binary logis-
tic regression model, including all variables that were
associated with the outcome (P < 0.05) in univariate
analysis. To compare the efficacy of LPV/r and ATV/r
based second line regimen, virological suppression was
assessed at one year by comparing patients started on
LPV/r based second line treatment between 2008 and
April 2010 and a VL report before change of therapy to
ATV/r with those newly started on ATV/r based regi-
men after May 2011with 6 or 12 month VL.
In survival analysis, patients started on second line ther-
apy between 2008 and 2012 were included. Status of these
patient was assessed in December 2013, so that all sub-
jects had the potential to complete a minimum of 1 year
of follow-up. The main outcome variable was death and
the time of its occurrence during the follow up period.
The data was treated as censored when either patients
were lost-to follow up or transferred-out to other ART
centres. The predictor variables used in the analysis were
duration of immunological failure, WHO criteria for im-
munological failure, weight, WHO clinical stage, CD4
count, presence of tuberculosis, adherence at the start of
both first and second line treatment and age, sex, viral
load at the beginning of second line treatment. Variables
that were statistically significant (p value <0.05) in the bi-
variate analysis were subsequently considered for multi-
variate analysis (Cox proportional hazard model) to assess
the relationship between these variables and mortality.
Results
Two hundred two patients were started on second line
ART between December 2008 and December 2012, out
of which 7 were already on therapy from outside and 25
were transferred out to other centre before six month
viral load thus only 170 patients were included in the
analysis.
Chakravarty et al. BMC Infectious Diseases  (2015) 15:517 Page 4 of 11Baseline characteristics of patient started on second line
therapy are given in Table 1. 82.9 % were males, median
duration of second line therapy was 22.50 months (IQR-
14-40.25). 33 (19.4 %) patients had tuberculosis during
second line treatment and adherence during second line
was > 95 % in 132 (77.6 %) patients. All patients received
TDF and 3TC as a part of second line regimen. Among
PI, 12 patients received only LPV/r (as they had expired
before change to ATV/r), 79 received both LPV/r and
ATV/r and 79 received only ATV/r based PI regimen.
Median CD4 count at the start of second line therapy was
78.50/μL (IQR 49.75–121.25), at 12 months 273/μL (IQR
182–357), at 24 month 319/μL (IQR 221–452), at 36 month
315/μL (IQR 209–467), at 48 month 285/μL (IQR 242–473)
and at 60 month 343 /μL (IQR 228–504).
Survival
At the end of follow up, out of the 170 patients started
on second line therapy, 35 (20.6 %) had expired, 5Table 1 Baseline characteristics of patients on second line (2nd Line
Variable
Age(years) Mean ± S
Median
Sex Male n (
Female n
Duration of Immunological failure (months) Mean ± S
Median
Weight(Kg) at the start of 2nd line ART Mean ± S
Median
Clinical Stage at the start of 2nd line ART I + II n (%
III + IV n
CD4 count at the start of 2nd line ART (/μL) Mean ± S
Median
Viralload baseline (copies/ml) Mean ± S
Median
Last NRTI regimen Stavudin
Zidovud
Total Duration of 2nd line ART (months) Mean ± S
Median
Tuberculosis during 1st line ART Yes n (%
No n (%
Tuberculosis during 2nd line ART Yes n (%
No n (%
1st line ART Adherence Adheren
Adheren
2nd line ART Adherence Adheren
Adheren
aInter quartile range(2.9 %) were lost to follow up, 20 (11.8 %) were trans-
ferred out to other ART centres and 110 (64.7 %) were
alive and on ART.
Out of the 35 patients who died, 21 (60 %) expired
within 12 months of starting second line. Among them 10
had tuberculosis, one each had pneumonia, oesophageal
candidiasis and diarrhea and no cause was documented in
8 patients. Among these 21 patients, viral load at 6 month
was not done in 17 patients due to death, 1 had virological
failure, 2 patients had adequate virological suppression
and 1 had ongoing viremia.
14 patients expired after 1 year of second line. Among
them 2 had tuberculosis, one each had anal carcinoma,
carcinoma penis, chronic renal failure and HIV enceph-
alopathy. Among these 14 patients 6 had virological fail-
ure, 1 had ongoing viremia, rest had adequate virological
suppression. The risk of death in the first year of therapy
was 13.7/100 person years while between 1 and 5 year it
was 3.88/100 person years.) ART
Number (n = 170)




D 17.30 ± 15.71
(IQR)a 12 (6.0-23.0)




D 94.36 ± 72.98
(IQR)a 78.50 (49.75-121.25)
D 490000.00 ± 1150000.00
(IQR)a 1770000 (67375–3540000)
e n (%) 81 (47.6)
ine n (%) 89 (52.4)






ce (<80-95 % ) n (%) 46 (27.1)
ce (>95 %) n (%) 124 (72.9)
ce (<80 %-95 %) n (%) 38 (22.4)
ce (>95 %) n (%) 132 (77.6)
Table 2 Univariate and multivariate analysis of survived and expired patients within 1 year and beyond 1 year
Within 1 year 1-5 year
Characteristics Uni-variate p- value Multi-variate p- value Uni-variate p-value Multi-variate p-value
HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI)
Age (years)
>40 1.718 (0.712-4.145) 0.229 2.508 (0.879-7.154) 0.086
≤40 1 1
Sex
Male 2.059 (0.480-8.839) 0.331 0.508 (0.158-1.630) 0.255
Female 1 1
WHO Stage 1st line
III + IV 2.616 (1.111-6.162) 0.028 0.710 (0.202-2.499) 0.594 1.956 (0.677-5.652) 0.215
I + II 1 1 1
Tuberculosis 1st line
Yes 1.218 (0.513-2.891) 0.654 1.001 (0.346-2.894) 0.998
No 1 1
Adherence 1st line
<95 % 1.115 (0.433-2.874) 0.822 5.673 (1.778-18.094) 0.003 5.226 (1.587-17.210) 0.007
>95 % 1 1 1
Weight (Kg) 1st line
≤45 0.867 (0.350-2.149) 0.759 2.407 (0.826-7.013) 0.107
>45 1 1
CD4 count 1st line (/μL)
<200 4.989 (0.670-37.178) 0.117 28.304 (0.085-924.0) 0.259
>200 1 1
Duration of Immunological failure (months)
>12 3.262 (1.182-11.123) 0.024 4.218 (1.146-15.519) 0.030 2.684 (0.824-8.745) 0.101
< 12 1 1 1
Clinical failure
Yes 2.721 (1.098-6.743) 0.031 1.056 (0.240-4.645) 0.943 0.640 (0.143-2.869) 0.560)
No 1 1 1
CD4 count less than baseline
Yes 3.579 (1.204-10.638) 0.022 4.111 (1.050-16.096) 0.042 2.120 (0.709-6.343) 0.179 3.328 (1.031-10.742) 0.044
No 1 1 1 1
50 % fall from peak CD4 count
Yes 0.448 (0.174-1.154) 0.096 25.70 (0.038-1719.0) 0.328
No 1 1
CD4 count < 100/μL
Yes 2.100 (0.815-5.413) 0.125 3.038 (0.847-10.895) 0.088
No 1 1
CD4 count 2nd line (/μL)
<200 0.644 (0.150-2.765) 0.554 22.856 (0.003-1692.0) 0.491
>200 1 1
WHO Stage 2nd line
III + IV 15.854 (4.666-53.872) <0.001 11.871 (2.695-52.296) 0.001 1.446 (0.484-4.318) 0.509
I + II 1 1 1
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Table 2 Univariate and multivariate analysis of survived and expired patients within 1 year and beyond 1 year (Continued)
Weight (Kg) 2nd line
≤45 6.491 (1.512-27.877) 0.012 15.777 (1.734-143.535) 0.014 1.089 (0.363-3.269) 0.879
>45 1 1 1
Viral Load 2nd Line (copies/ml)
>177000 2.042 (0.824-5.061) 0.123 0.790 (0.274-2.279) 0.662
≤177000 1 1
Tuberculosis 2nd line
Yes 4.219 (1.791-9.939) 0.001 2.336 (0.752-7.256) 0.142 0.854 (0.190-3.837) 0.837
No 1 1 1
Adherence 2nd line
<95 % 1.483 (0.575-3.821) 0.415 14.682 (4.093-52.660) <0.001 15.838 (4.274-58.685) <0.001
>95 % 1 1 1
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>12 months [HR 4.218; 95 % CI: 1.146-15.519], presence
of WHO immunological criteria CD4 count less than
pretherapy (at the start of first line) baseline [HR 4.111;
95 % CI: 1.050-16.096]; weight <45 kg [HR 15.777; 95 %
CI: 1.734 -143.535],WHO clinical stage 3 and 4 [HR
11.871; 95 % CI: 2.695-52.296] had higher risk of death.
Beyond first year, patients with CD4 count less than
pretherapy baseline [HR 3.328; 95 % CI: 1.031-10.742],
poor adherence during first line [HR 5.226; 95 % CI:
1.587-17.210] as well as during second line therapy
[HR 15.838; 95 % CI: 4.274-58.685] had higher risk of
death (Table 2).
Efficacy
At 6 months viral load was done in 152 patients as 17 had
expired and 1 was LFU. 102 patients had a viral load of
<400 copies/ml, 12 had viral load between 400 and 1000
copies/ml and 38 had viral load >1000 copies/ml. At
12 months viral load was repeated in only 41 patients out
of the 50 patients whose VL was >400 copies/ml at six
month, as 5 expired and 4 were LFU. Among these 41 pa-
tients, 17 had VL <400 copies/ml, 5 had VL between 400
and 1000 copies/ml and 19 had viral load >1000 copies/ml.
Overall, out of 170 patients who were started on sec-
ond line, 119/170 i.e. 70 % by ITT and 119/152 i.e.
78.2 % by OT had adequate virological response, 6
(3.5 % ITT, 3.9 % OT) had ongoing viremia and 27
(15.8 % ITT, 17.7 % OT) had virological failure at one year.
Viral load ≥177,000 copies/ml at baseline (OR 3.402,
95 % CI: 1.272-9.097) and <95 % adherence during second
line treatment (OR 2.788, 95 % CI: 1.044-7.445) was
significantly associated with second line failure (Table 3).
On comparing the efficacy of LPV/r vs ATV/r, the two PIs
used as second line, 85.2 % (46/54) had virological
suppression with LPV/r while 69 % (49/71) had virological
suppression with ATV/r at one year.HIVDR genotyping
Out of the 27 patients who failed second line therapy 3
expired and 2 were LFU and sample for genotyping
could not be collected in 3 patients. Out of the 19 sam-
ples available, genotyping data of only 16 patients could
be included in the study as sample (SL) 7, 17 and 18 did
not amplify. All samples were HIV 1 virus subtype C.
50 % (8/16) had major PI mutation, 62.5 % (10/16) had
minor PI mutation, 81.25 % (13/16) had NRTI mutation
and 93.75 % (15/16) had NNRTI (non nucleoside reverse
transcriptase) mutation (Table 4). Median GSS was 1.0
(0–1.81).
Among PI mutations, M46I (n = 5) was the common-
est mutation, followed by N88S (n = 3), I50L (n = 2),
I84V (n = 2), V 82A (n = 1). 6 patients with >12 months
of second line therapy as compared to 2 patients with
<12 months therapy had at least one major PI mutation.
Fourteen (87.5 %) patients were susceptible to darunavir
(DRV) while two were associated with low level resist-
ance to DRV. 6 (37.5 %) patients were associated with
high resistance, 3 (18.75 %) had low level resistance and
7 (43.75 %) were still susceptible to atazanavir (ATV).
M184V was the commonest NRTI mutation and was
present in 13 out of 16 patients. 62.5 % (n = 10) patients
had ≥3 TAM (Thymidine analogue mutations). 81.25 %
(n = 13) had more than 1 NNRTI mutation.Y181C and
G190A was the most common NNRTI mutation present
in 37.5 % (n = 6) patient each. ESS were ≥ 2.5 in 56.25 %
(9/16) patients.
Discussion
This study reports the outcome of patients receiving sec-
ond line antiretroviral therapy under the National AIDS
control programme of India. Retention in care at the
end of follow up was similar to a study from rural South
Africa where routine virological monitoring is done.
While in our study mortality was higher, lost to follow
Table 3 Univariate and multivariate analysis between virological Failure and adequate virological response
Characteristics Uni-variate p-value Multi-variate p-value
Odds ratio (95 % CI) Odds ratio (95 % CI)
Age (years)
>40 1.249 (0.496-3.147) 0.637
≤40 1
Sex
Male 0.423 (0.161-1.112) 0.081
Female 1
WHO Stage 1st line
III + IV 1.038 (0.400-2.698) 0.938
I + II 1
Tuberculosis 1st line
Yes 2.327 (0.968-2.327) 0.059
No 1
Adherence 1st line
<95 % 2.600 (1.090-6.201) 0.031 1.918 (0.741-4.962) 0.180
>95 % 1 1
Weight (Kg) 1st line
≤45 1.215 (0.517-2.854) 0.655
>45 1
CD4 count 1st line (/μL)
<200 3.618 (1.455-8.998) 0.006 2.788 (1.045-7.439) 0.041
>200 1 1
Duration of Immunological failure (months)
>12 0.542 (0.229-1.283) 0.164
<12 1
Clinical failure
Yes 5.253 (0.673-40.976) 0.114
No 1
CD4 count less than baseline
Yes 2.335 (0.949-5.749) 0.065
No 1
50 % fall from peak CD4 count
Yes 1.092 (0.339-3.519) 0.882
No 1
CD4 count < 100/μL
Yes 0.688 (0.297-1.593) 0.382
No 1
CD4 count 2nd line (/μL)
<200 3.275 (0.856-12.537) 0.083
>200 1
WHO Stage 2nd line
III + IV 1.287 (0.477-3.477) 0.618
I + II 1
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Table 3 Univariate and multivariate analysis between virological Failure and adequate virological response (Continued)
Weight (Kg) 2nd line
≤45 1.143 (0.492-2.653) 0.756
>45 1
Viral Load 2nd Line (copies/ml)
>177000 3.558 (1.399-9.050) 0.008 3.402 (1.272-9.097) 0.015
≤177000 1 1
Tuberculosis 2nd line
Yes 1.364 (0.455-4.090) 0.580
No 1
Adherence 2nd line
<95 % 2.870 (1.176-7.004) 0.021 2.788 (1.044-7.445) 0.041
>95 % 1 1
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[14]. Early mortality was high in our study but was com-
parable to a study from Malawi where WHO defined
immunological and clinical failure criteria were used to
detect first line failure similar to our study [2]. Risk fac-
tor for early death (within one year) in our study was
duration of immunological >12 months, presence of
WHO immunological criteria, CD4 count less than pre-
therapy, weight <45 kg, WHO clinical stage III &IV, all
of which suggests that patients failing first line for a long
time and those in poor clinical condition at the start of
second line were at increased risk of death. Similar find-
ings were observed in the study from Malawi where clin-
ical failure at baseline and body mass index <18.5 were
risk factors for death [2].
These finding suggests that delay in detecting first line
failure may be the main reason for this high early mor-
tality in our study. Studies have shown that WHO im-
munological failure criteria have low sensitivity for
detecting virological failure [15, 16]. Moreover, the cut
off viral load level for starting second line in our study
was much higher (5000–10,000 copies/ml) as compared
to other studies [2, 14]. A recent study from Africa has
shown that delayed switch of antiretroviral therapy after
virological failure is associated with increased mortality
[17]. Decreasing the cut–off level for viral load for start-
ing second line to 1000 copies/ml and ensuring early re-
ferral through education of medical officers are some of
the initiatives taken by NACO which will decrease the
mortality among second line patients in future. However,
increasing the accessibility of viral load testing as recom-
mended by the recent WHO guidelines would definitely
go a long way in improving the second line program.
Efficacy analysis showed that 119 (70 % by ITT, 78.2 %
OT) had adequate virological response at one year.
Similar findings were observed in studies from other re-
source limited settings [4, 14], while a study from Indiashowed slightly better outcome [5]. A recent large trial
from Africa has shown adequate virological suppression
in 86 % of patients at 96 weeks with the WHO recom-
mended second line regimen of NRTI and boosted PI
[18]. High early mortality, higher viral load cut off for
starting therapy in our study could be the reasons for
the difference in virological response from this study.
Poor adherence during second line therapy was an im-
portant risk factor for virological failure in our study
similar to other studies [2, 3, 19]. Poor adherence was
also a major risk for death beyond first year in our study.
The fact that 50 % (7/14) of our patients who died after
one year of therapy did not have adequate virological
suppression, suggests that poor adherence might have
led to virological failure and death.
Interestingly, 17/50 (34.0 %) of our patients who had
ongoing viremia or virological failure at 6 months ad-
equately suppressed their viral load at 12 months. Simi-
lar findings were observed in a study where 62 %
patients suspected of second-line ART failure, responded
to enhanced adherence support and had a two-log de-
crease in their level of HIV on subsequent VL testing
[20]. These findings further endorses the WHO guide-
lines which recommends that patients failing virologic-
ally be subject to an adherence support intervention,
after which a second viral load test should be performed
prior to deciding on a regimen change. High viral load
at baseline as a risk factor for virological failure was also
recently observed in the results of TREAT Asia HIV ob-
servational database [21].We observed that virological
suppression was better in those with LPV/r as compared
to ATV/r, however, as this analysis included only a small
subset of patients further studies are needed to come to
any conclusions.
This is the first study to report the mutations acquired
by second line failure patients in the National program.
Median GSS was very low (1.0) in our study. 62.5 %
Table 4 Mutations acquired by patients failing second line treatment
Patient ID Gene BankAccession
No.












SL-1 KJ933454 46 >95 % C M46I, I47A,
I50IL, I84V
A71V M41L, D67N, K70R, L74IL,
M184V, T215Y, K219Q
K103N, K238KN 0 0
SL-2 KJ933455 13 >95 % C NONE NONE M41L, D67N, M184V,
T215F, K219W
Y181V, G190A 1.25 4
SL-3 KJ933456 23 >95 % C M46I, N88S L24I, Q58E,
A71V
M41L, K65R, K70T, M184V A98G, K101E, G190A 0 3
SL-4 KJ933457 9 >95 % C NONE NONE M184V K101E, G190A 2 2
SL-5 KJ933458 20 >95 % C M46I L23IL D67N, V75M, M184V Y181C 1.25 2.5
SL-6 KJ933459 24 >95 % C None K20I, L90LW None V108IV, Y181C, H221Y 3 2.5




M41L, D67N, V75M, M184V,
L210W, T215Y, K219N
A98G, K103N 0 1




K101H, Y181CFIS, G190A 0 7.5
SL-12 KJ933464 14 >95 % C NONE K20KT, G73S M41L, D67E, V75M, M184V,
L210W, T215Y
V90I, V108I, Y181C 0.5 3.5
SL-13 KJ933465 10 >95 % A1C I84IV L23I, A71V M41L, D67N, L74I, V75M,
M184V, L210W, T215Y,
K219N
A98G, K103N, G190 0 2
SL-14 KJ933466 9 <95 % C None None None None 3 0
SL-15 KJ933467 20 >95 % C NONE NONE M41L, D67N, V75M, M184V,
T215Y, K219N
V90I, K103N 1.25 1





SL-19 KJ933469 12 <95 % C NONE NONE NONE K101E 3 1





SL-21 KJ933471 18 <95 % C N88S L10F, K20T,
Q58E
D67N, T69D, K70R, M184V,
T215F, K219Q
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during first line therapy and suggests that patients were
failing on first line therapy long before detection. It also
implies that they were relatively on PI monotherapy and
at risk of developing PI mutations. 93.75 % of the pa-
tients in our study had NNRTI mutation, which may be
due to re-emergence of archived mutations from first-
line NNRTI regimens. Etravirine susceptibility scores
(ESS) was ≥ 2.5 in 56.25 % patients, which is a concern
as best virologic suppression are seen when the ESS
score is less than or equal to 2.0 and this drug is also a
part of the WHO recommended third line regimen.
50 % of our second line failure patients had major PI
mutation which is much higher than previous studies
[22, 23] but is similar to a recent study from Nigeria and
a tertiary care centre in India [24, 25]. Patients with lon-
ger duration of therapy had more chances of acquiring
PI mutation in our study, similar to the study from
Nigeria [24]. Studies have shown that several Gag sub-
strate mutations can cause drug resistance mutations
that confer PI resistance in the absence of protease mu-
tations [26–28]. This could explain the fact that only
50 % of the patients had PI mutation while all of them
were failing second line. M46I was the commonest PI
mutation observed in our study which reduces suscepti-
bility to all PI except darunavir [11]. Similar findings
were observed in other studies from India, [25, 29]. As
M46I mutation has also been observed in few PI naïve
patients we could have slightly overestimated the
selection of this mutation in our study as genotyping
was not performed before the start of second line ther-
apy [30, 31]. N88S was the second most common PI
mutation in our study which is associated with resist-
ance to ATV/r and nelfinavir. Only two patients had
I84V mutation which confers broad spectrum resistance
to all PIs and low level resistance to DRV. Thus, most
patients were still susceptible to DRV the recommended
PI for third line regimen by WHO.
The major limitations of our study was the inability to
do viral load testing for all patients at 12 months and
the fact that genotyping was not done at the start of
second line therapy.
Conclusion
In this observational study there was high early mortality
but good long term outcome as well as virological sup-
pression in patients starting second line therapy under
programmatic conditions in India. This early mortality
can be circumvented by introducing routine virological
monitoring in the program which will help in early de-
tection of patients with failure. Virological response in
our cohort was similar to other resource poor settings.
Although 50 % of our second line failure patients had
major PI mutation most were still susceptible to darunavir.Thus, darunavir in combination with integrase inhibitor
which has not been used in the program remains a good
option as a third line ART for the National program.
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